Bloks Group Limited — M&A Activity 2001

Feb 9, 2001

The Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

HONG KONG PHARMACEUTICAL HOLDINGS LIMITED

香 港 葯 業 集 團 有 限 公 司*

(Incorporated in Bermuda with limited liability)

DELAY IN DESPATCH OF MAJOR TRANSACTION CIRCULAR

Reference is made to the announcement of Hong Kong Pharmaceutical Holdings Limited (the “Company”) dated 16 January 2001 (the “Announcement”) in relation to the proposed acquisition by China Genetic Limited, an indirect wholly owned subsidiary of the Company, of 57% equity interest in Shanghai Hua Xin High Biotechnology Inc. Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcement.

According to Rule 14.13(2) of the Listing Rules, a circular containing information regarding the Acquisition (the “Circular”) is required to be despatched to shareholders of the Company on or before 7 February 2001. Due to the intervening Chinese New Year break, the Company required more time to prepare the Circular and has therefore applied to the Stock Exchange for an extension for the despatch of the Circular. The Circular has been despatched to shareholders of the Company on 8 February 2001 for their information.

By Order of the Board of Directors

HONG KONG PHARMACEUTICAL HOLDINGS LIMITED

Huang Shuyun

Deputy Chairman and Managing Director

Hong Kong, 8 February 2001

* For identification only

Please also refer to the published version of this announcement in the i Mail dated 9/2/2001.